Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Humphrey Gardner

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|May 22, 2007
Novel insight into the agonistic mechanism of alefacept in vivo: differentially expressed genes may serve as biomarkers of response in psoriasis patientsAsifa S Haider, Michelle A Lowes, Humphrey Gardner, et al.
British Journal of Clinical Pharmacology|April 27, 2025
A novel approach for first-in-human dose selection using population dose-response modelling to find a minimum anticipated biological effect levelLin Yuan, Meghana Kulkarni, Evan Chiswick, et al.
Antimicrobial Agents and Chemotherapy|December 24, 2014
Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeaeRichard A Alm, Sushmita D Lahiri, Amy Kutschke, et al.
Pigment Cell & Melanoma Research|December 24, 2010
A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation statusMarie C Zipser, Ossia M Eichhoff, Daniel S Widmer, et al.
Pharmacogenomics|December 19, 2007
Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patientsMizutomo Azuma, Michael Shi, Kathleen D Danenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2017
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell CancerToni K Choueiri, Elizabeth Plimack, Hendrik-Tobias Arkenau, et al.
Breast Cancer Research and Treatment|October 22, 2009
Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancerMatthew J Ellis, Li Lin, Robert Crowder, et al.
Frontiers in Cellular and Infection Microbiology|January 30, 2023
Development of a novel loop-mediated isothermal amplification assay for ß-lactamase gene identification using clinical isolates of Gram-negative bacteriaEun Jin Kim, Jiwon Lee, Youngbae Yoon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2015
PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab ResistanceHoward M Stern, Humphrey Gardner, Tomasz Burzykowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2009
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancerJosé Baselga, Vladimir Semiglazov, Peter van Dam, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Journal of Immunology (Baltimore, Md. : 1950)|May 22, 2007
Novel insight into the agonistic mechanism of alefacept in vivo: differentially expressed genes may serve as biomarkers of response in psoriasis patientsAsifa S Haider, Michelle A Lowes, Humphrey Gardner, et al.
British Journal of Clinical Pharmacology|April 27, 2025
A novel approach for first-in-human dose selection using population dose-response modelling to find a minimum anticipated biological effect levelLin Yuan, Meghana Kulkarni, Evan Chiswick, et al.
Antimicrobial Agents and Chemotherapy|December 24, 2014
Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeaeRichard A Alm, Sushmita D Lahiri, Amy Kutschke, et al.
Pigment Cell & Melanoma Research|December 24, 2010
A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation statusMarie C Zipser, Ossia M Eichhoff, Daniel S Widmer, et al.
Pharmacogenomics|December 19, 2007
Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patientsMizutomo Azuma, Michael Shi, Kathleen D Danenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2017
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell CancerToni K Choueiri, Elizabeth Plimack, Hendrik-Tobias Arkenau, et al.
Breast Cancer Research and Treatment|October 22, 2009
Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancerMatthew J Ellis, Li Lin, Robert Crowder, et al.
Frontiers in Cellular and Infection Microbiology|January 30, 2023
Development of a novel loop-mediated isothermal amplification assay for ß-lactamase gene identification using clinical isolates of Gram-negative bacteriaEun Jin Kim, Jiwon Lee, Youngbae Yoon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2015
PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab ResistanceHoward M Stern, Humphrey Gardner, Tomasz Burzykowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2009
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancerJosé Baselga, Vladimir Semiglazov, Peter van Dam, et al.
Pageof 6